Eli Lilly & Co. said it entered an exclusive agreement to develop privately held biopharmaceutical firm Zosano Pharm Corp.’s experimental microneedle patch system to treat severe osteoporosis in a deal potentially valued at as much as $440 million.
via WSJ.com: US Business http://ift.tt/1pNvtp6
via WSJ.com: US Business http://ift.tt/1pNvtp6
Nessun commento:
Posta un commento